7MM Intra-tumoral cancer therapies market eyes 31.3% CAGR growth until 2034

However, a lack of standardised guidelines may affect growth.

The intra-tumoral cancer therapies market across seven major markets is projected to expand at a compound annual growth rate of 31.3% until 2034, according to DelveInsight.

The sector’s expansion is attributed to the introduction of emerging therapies and further improvements in diagnosis rates.

“Radio enhancer nanoparticles, recombinant fusion proteins, oncolytic therapy, gene therapy, synthetic dsRNA complexes, and others, are currently in preclinical and clinical development,” the report said.

However, a lack of standardised guidelines for intra-tumoral immunotherapy delivery—covering lesion selection, injection frequency, and needle technique—may impede growth.

Several therapies, such as tilsotolimod/Ipilimumab, sotigalimab, and vidutolimod, have failed clinical trials.

“Tumours with high intra-tumoral heterogeneity may lead to poorer clinical outcomes for patients,” it added.

*7MM = US, Germany, France, Italy, Spain, UK, and Japan